# The source belongs next to the claim.

Here's where the explanations lead: research papers, medicine labels and FDA pages. Each note says what the source adds. Follow the question that interests you; there's no need to read the whole shelf. These sources explain research and products, not a personal treatment plan.

## Tesamorelin in adults with HIV and abdominal fat accumulation

Falutz and colleagues, 2007. The trial measured fat around the organs in adults with HIV. Its result belongs to that group.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/18057338/)

## What happened during continued tesamorelin treatment and after stopping

Falutz and colleagues, 2008. In adults with HIV and extra abdominal fat, the reduction in fat around the organs held during treatment; fat built up again after stopping.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/18690162/)

## Tesamorelin prescribing information (Egrifta WR)

The U.S. label gives the HIV-related approved use, safety warnings and monitoring. It says tesamorelin isn't for weight-loss management.

[Read the source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)

## STEP 1 and semaglutide in adults without diabetes

Wilding and colleagues, 2021. Adults had obesity, or overweight with a weight-related condition, without diabetes. This is the injected semaglutide study discussed here.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/33567185/)

## A review of semaglutide safety

Smits and Van Raalte, 2021. The review covers stomach and bowel effects and gallbladder concerns. Those belong beside the weight findings.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/34305810/)

## Wegovy prescribing information for semaglutide

The U.S. label covers forms, uses and warnings. Thyroid tumors were seen in rodents; whether semaglutide causes them in people is unknown.

[Read the source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)

## SURMOUNT-1 and assigned tirzepatide amounts

Jastreboff and colleagues, 2022. Different tirzepatide groups had different average weight losses. The study doesn't pick an amount for an individual.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/35658024/)

## Tirzepatide, pancreatitis and gallbladder or biliary disease

Zeng and colleagues, 2023. This review examined pancreatitis and gallbladder or bile-duct problems. Its uncertain pancreatitis estimate cannot rule out increased risk.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/37908750/)

## Zepbound prescribing information for tirzepatide

The U.S. label sets out uses and warnings, including thyroid tumors seen in rats. The relevance to people remains unknown.

[Read the source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)

## Ipamorelin blood levels and hormone response in healthy men

Gobburu and colleagues, 1999. Infusions into a vein in healthy men produced a short hormone pulse. This wasn't a sleep or recovery test.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/10496658/)

## Ipamorelin after bowel surgery

Beck and colleagues, 2014. After bowel surgery, the trial didn't establish a clear benefit on its main measure: tolerating a meal sooner.

[Read the source](https://pubmed.ncbi.nlm.nih.gov/25331030/)

## FDA's assessment of ipamorelin-related substances

FDA's 2024 assessment discusses evidence gaps and serious events in the surgery trial. It doesn't establish that ipamorelin caused the deaths.

[Read the source](https://www.fda.gov/media/182088/download)

## FDA's bulk-substance safety concerns

On this page current as of April 22, 2026, ipamorelin acetate appears in 503B Category 2 and among withdrawn nominations. Withdrawal isn't clearance.

[Read the source](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)

## FDA explains compounded medicines

FDA explains why compounded drugs are not FDA-approved. An approved ingredient name doesn't give every preparation the approval of a manufactured medicine.

[Read the source](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)

## FDA's concerns about unapproved GLP-1 drugs

FDA describes risks with unapproved semaglutide and tirzepatide, including dosing errors. Its advice points to prescriptions and state-licensed pharmacies.

[Read the source](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)

---

Every amount, in company.

Dose Peptide is a guide to reading an amount in context, not a clinic, a pharmacy or a seller.

© 2026 Dose Peptide